Form 4: Whitehawk Therapeutics Director Anupam Dalal Granted 40,006 Stock Options

Anupam Dalal, a Director and 10% owner of Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Summary

• Anupam Dalal, a Director and 10% Owner of Whitehawk Therapeutics, Inc. (WHWK), was granted 40,006 stock options.
• The transaction date for the stock option grant was June 12, 2025.
• The exercise price for these stock options is $2.04 per share.
• The options are for Common Stock, with 40,006 shares underlying the derivative security.
• The options will vest 100% on the earlier of the one-year anniversary of the grant date (June 12, 2025) or the day immediately prior to the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon the Reporting Person continuing to be a Service Provider as defined in the Issuer's 2021 Equity Incentive Plan.
• The expiration date for these stock options is June 12, 2035.
• Following this transaction, Anupam Dalal beneficially owns 40,006 derivative securities (stock options) directly.
• Anupam Dalal has granted a Power of Attorney to several individuals, including David Lennon, Scott Giacobello, Stephen Rodin, Daniel Koeppen, Robert Wernli, Michael Brito-Stamm, and Bridget Balisy, to prepare and file SEC reports on his behalf, effective April 25, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates an insider receiving equity compensation, which aligns their interests with shareholders. However, it's a routine filing and doesn't contain significant new operational or financial news.

Positives

• The grant of stock options to a Director and 10% owner aligns their interests with long-term shareholder value, incentivizing performance.
• The vesting schedule encourages continued service and commitment from a key insider.

Negatives

• The exercise price of $2.04 is a future price, and the value of the options is dependent on the stock price exceeding this amount.

Risks

• The vesting of the stock options is subject to the Reporting Person continuing to be a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The document indicates future vesting of stock options for a key insider, contingent on continued service, suggesting an expectation of ongoing commitment from the director.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across all publicly traded companies. It reflects a standard practice of incentivizing directors and key personnel through equity grants, aligning their financial interests with the company's performance.

Comparison to Industry Standards

• The grant of stock options to directors is a common compensation practice across industries, including the biotechnology and pharmaceutical sectors where Whitehawk Therapeutics likely operates.
• The vesting schedule, typically over one to four years, is standard for equity incentive plans, aiming to retain talent and align long-term interests. A one-year vesting period for 100% of the grant is relatively aggressive, potentially indicating a desire for immediate alignment or a shorter-term performance focus for this specific grant.
• The exercise price being a fixed value at the time of grant is standard for non-qualified stock options, providing upside potential if the company's stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the options gain value only if the company's stock price increases.
• Employees: The vesting condition tied to being a 'Service Provider' is a standard practice in equity incentive plans, potentially impacting the director's long-term commitment to the company.

Next Steps

• The stock options will vest on the earlier of June 12, 2026 (one-year anniversary of grant) or the day prior to the next annual meeting of stockholders following the grant date.
• The Reporting Person will continue to be subject to SEC filing requirements for changes in beneficial ownership.

Key Dates

Recommendation

Keywords

Stock Options, SEC Form 4, Beneficial Ownership, Insider Trading, Equity Incentive Plan, Director Compensation, Whitehawk Therapeutics, WHWK, Vesting, Derivative Securities